Resource Logo
NLM AIDSLINE

Zidovudine treatment in HIV-infected intravenous drug users. Compliance with long-term treatment and efficacy.




 

Int Conf AIDS. 1990 Jun 20-23;6(3):198 (abstract no. S.B.450). Unique

OBJECTIVE: To assess the compliance with long-term zidovudine treatment and the efficacy of therapy in a cohort of intravenous drug users (IVDUs). METHODS: Eighty-six HIV-infected IVDUs were treated with oral zidovudine for 3-24 months in an outpatient setting. A retrospective, historical control group of 127 IVDUs was selected according to disease staging. RESULTS: Cumulative probability of voluntary zidovudine discontinuation was 9% at 3 months, 29% at 6 months, and 38% at 9 months. No more drop outs occurred after 9 months of treatment. Monitoring of mean corpuscolar volume of red blood cells well correlated with time of treatment. Patients receiving zidovudine showed a cumulative probability of survival at 12 months of 88+/-9.8%, as compared with 50+/-8.6% in untreated patients (P less than 0.001). Less opportunistic infections occurred among zidovudine treated subjects than among untreated patients (4 vs. 15, respectively, after 12 months; P less than 0.001). Marrow toxicity was the most relevant toxic effect observed. CONCLUSION: Acceptable rates of compliance with long-term zidovudine treatment are attainable in IVDUs. Survival data and incidence of opportunistic infections show that HIV-infected IVDUs can benefit from continued zidovudine treatment.

Bone Marrow Diseases/CHEMICALLY INDUCED/COMPLICATIONS Human HIV Infections/*DRUG THERAPY/EPIDEMIOLOGY Incidence Italy/EPIDEMIOLOGY Longitudinal Studies Opportunistic Infections/COMPLICATIONS/DRUG THERAPY Outpatients *Patient Compliance Retrospective Studies *Substance Abuse, Intravenous/COMPLICATIONS Survival Analysis Zidovudine/ADVERSE EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE ABSTRACT



 




Information in this article was accurate in December 30, 1990. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.